Download PDF
Thromb Haemost 1993; 69(04): 306-310
DOI: 10.1055/s-0038-1651602
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

The Course of Preexistent Immune Abnormalities in HIV Negative Haemophiliacs Treated for Two Years with a Monoclonal Purified Factor VIII Concentrate

W M Smid
The Department of Haematology, Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, The Netherlands
,
J van der Meer
The Department of Haematology, Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, The Netherlands
,
J W Smit
The Department of Haematology, Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, The Netherlands
,
M R Halie
The Department of Haematology, Division of Haemostasis, Thrombosis, and Rheology, University Hospital Groningen, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 05 June 1992

Accepted after revision 01 December 1992

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The administration of factor VIII concentrates has been associated with immune abnormalities in patients with severe haemophilia A, even in the absence of HIV infection.

The effects of a monoclonal purified factor VIII concentrate, Hemofil M (Baxter), on preexistent immune abnormalities were assessed over a 2 year period in 22 HIV negative haemophiliacs. They were treated previously with other concentrates, and received Hemofil T from 1983 to 1988. No HIV infection was demonstrated. No serologic evidence for other viral (re)-infections was seen. A decrease of HLA-DR expression on non-B lymphocytes in the first year (P = 0.026), and a decrease of T4-T8 ratio over the 2 years were found (P = 0.0016). Skin tests were non-contributive. The decrease in HLA-DR expression is suggestive for an improved immune function, possibly due to a reduced content of protein or virus in this concentrate.

 

  • References

  • 1 Anonymous. Blood transfusions, haemophilia, and AIDS. Lancet 1984; ii: 1433-1435
    PubMedGoogle Scholar
  • 2 Goedert JJ, Sarngadharan MG, Eyster ME, Weiss SH, Bodner AJ, Gallo RC, Blattner WA. Antibodies reactive with human T cell leucaemia viruses in the serum of hemophiliacs receiving factor VIII concentrate. Blood 1985; 65: 492-495
    PubMedGoogle Scholar
  • 3 Ragni MV, Winkelstein A, Kingsley L, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B. Blood 1987; 70: 786-790
    PubMedGoogle Scholar
  • 4 Noel L, Guerois C, Maisonneuve P, Verroust F, Laurian Y. Antibodies to hepatitis C virus in haemophilia. Lancet 1989; ii: 560 (Letter)
    PubMedGoogle Scholar
  • 5 Jones PK, Ratnoff OD. The changing prognosis of classic hemophilia (factor VIII “deficiency”). Ann Intern Med 1991; 114: 641-684
    CrossrefPubMedGoogle Scholar
  • 6 McDougal JS, Martin LS, Cort SP, Mozen M, Heldebrant CM, Evatt BL. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophiliac factor. J Clin Invest 1985; 76: 875-877
    CrossrefPubMedGoogle Scholar
  • 7 Rouzzioux C, Chamaret S, Montagnier L, Carnelli V, Rolland G, Mannucci PM. Absence of antibodies to aids virus in heamophiliacs treated with heat-treated factor VIII concentrate. Lancet 1985; i: 271-2 (Letter)
    PubMedGoogle Scholar
  • 8 Meer Jvd, Daenen S, Imhoff GWv, Wolf JTMde, Halie MR. Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with factor VIII concentrate. Br Med J 1986; 292: 1049
    CrossrefPubMedGoogle Scholar
  • 9 Mannucci PM, Colombo M. Virucidal treatment of clotting factor concentrates. Lancet 1988; ii: 782-786
    PubMedGoogle Scholar
  • 10 Busch MP, Eble BE, Khayam-Bashi H, Heilbron D, Murphy EL, Kwok S, Sninsky J, Perkins HA, Vyas GN. Evaluation fo screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991; 325: 1-5
    CrossrefPubMedGoogle Scholar
  • 11 Kreis JK, Kitchen LW, Prince HE, Kasper CK, Goldstein AL, Naylor PH, Preble O, Stewart JA, Essex M. Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Am J Med 1986; 80: 345-350
    CrossrefPubMedGoogle Scholar
  • 12 Knutsen AP, Bouhasin JD, Joist JH, Scrivner D, Mueller KR, Gioia K, Janney S. Decrease of CD4 cell number and function in HIV-seropositive hemophiliacs in a longitudinal study. Ann Allergy 1989; 63: 189-194
    PubMedGoogle Scholar
  • 13 Weintrub PS, Koerper MA, Addiego JE, Drew L, Lennette ET, Miner R, Cowan MJ, Ammann AJ. Immunologic abnormalities in patients with hemophilia A. J Pediatr 1983; 103: 692-695
    CrossrefPubMedGoogle Scholar
  • 14 Kimberley RP, Inman RD, Bussel JB, Polk JR, Hilgartner M. Modulation of mononuclear phagocyte system function and circulating immunecomplexes by lyophilized concentrates in patients with classic hemophilia. Clin Immunol Immunopathol 1984; 31: 321-330
    CrossrefPubMedGoogle Scholar
  • 15 Mannhalter JW, Zlabinger GJ, Ahmad R, Zielinski CC, Schramm W, Eibl MM. A functional defect in the early phase of the immune response observed in patients with hemophilia A. Clin Immunol Immunopathol 1986; 38: 390-397
    CrossrefPubMedGoogle Scholar
  • 16 Mannhalter JW, Ahmad R, Leibl H, Gottlicher J, Wolf HM, Eibl MM. Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity. Blood 1988; 71: 1662-1668
    PubMedGoogle Scholar
  • 17 Pasi KJ, Hill FGH. In vitro and in vivo inhibition of monocyte phygocytic function by factor VIII concentrates: correlation with concentrate purity. Br J Haematol 1990; 76: 88-93
    CrossrefPubMedGoogle Scholar
  • 18 Lederman MM, Ratnoff OD, Shoger T. Antihemophilic factor preparations inhibit lymphocyte function & alter lymphocyte subsets in culture. Clin Research. 1984 32. suppl 313 (abstr)
    PubMedGoogle Scholar
  • 19 Lederman MM, Saunders C, Toossi Z, Lemon N, Everson B, Ratnoff OD. Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin-2. J Lab Clin Med 1986; 107: 471-478
    PubMedGoogle Scholar
  • 20 Madhok R, Gracie A, Lowe GDO, Burnett A, Froebel K, Follett E, Forbes CD. Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J 1986; 293: 978-980
    CrossrefPubMedGoogle Scholar
  • 21 Mahir WS, Millard RE, Booth JC, Flute PT. Functional studies of cell-mediated immunity in haemophilia and other bleeding disorders. Br J Haematol 1988; 69: 367-370
    CrossrefPubMedGoogle Scholar
  • 22 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387-391
    PubMedGoogle Scholar
  • 23 Hay CRM, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL2-receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990; 75: 278-281
    CrossrefPubMedGoogle Scholar
  • 24 Madhok R, Gracie JA, Smith J, Lowe GDO, Forbes CD. Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection. Br J Haematol 1990; 76: 70-74
    CrossrefPubMedGoogle Scholar
  • 25 Madhok R, Smith J, Jenkins A, Lowe GDO. T cell sensitization to factor VIII in haemophilia A?. Br J Haematol 1991; 79: 235-238
    CrossrefPubMedGoogle Scholar
  • 26 Gomez E, Alberca I, Gonzalez M, Zaballoz R, Vicente V. Effect of hepatitis C virus infection on the lymphoid population in hemophiliacs. Blood 1991; 77: 1399-1400
    PubMedGoogle Scholar
  • 27 Weinstein RE. Immunoaffinity purification of factor VIII. Ann Clin Lab Science 1989; 19: 84-91
    PubMedGoogle Scholar
  • 28 Seremetis S, Aledort LM. Sacks H and the monoclate study group Differential effects on CD4 cell counts of high or intermediate grade purity factor VIII concentrates in HIV + haemophiliacs: a metaanalysis. Blood 1990; 76 1624: 408a
    PubMedGoogle Scholar
  • 29 Mansour I, Doinel C, Rouger P. Dichotomy of two CD8 + lymphocyte subsets in HIV infection. Depletion of CD8 + CD3- and expansion of CD8 + CD3 + subsets: consequence on the CD4/CD8 ratio. Clin Exp Immunol 1991; 85: 481-484
    PubMedGoogle Scholar
  • 30 Prince HE, Kreiss JK, Kasper CK, Kleinman S, Saunders AM, Waldbeser L, Mandigo G, Kaplan HS. Distinctive lymphocyte subpopulation abnormalities in patients with congenital coagulation disorders who exhibit lymph node enlargement. Blood 1985; 66: 64-68
    PubMedGoogle Scholar
  • 31 Shannon BT, Roach J, Cheek-Luten M, Orosz C, Ruymann FB. Progressive change in lymphocyte distribution and degree of hyper-gammaglobulinemia with age in children with hemophilia. J Clin Immunol 1986; 6: 121-129
    CrossrefPubMedGoogle Scholar
  • 32 Sullivan JL, Brewster FE, Brettler DB, Forsberg AD, Cheeseman SH, Byron KS, Baker SM, Willitts DL, Lew RA, Levine PH. Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses. J Pediatrics 1986; 108: 504-510
    CrossrefPubMedGoogle Scholar
  • 33 Dianzani U, Pileri A, Bianchi A, Camponi A, Tamponi G, Massaia M. Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. Eur J Haematol 1988; 41: 334-340
    PubMedGoogle Scholar
  • 34 Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy. Br J Haematol 1992; 80: 364-369
    CrossrefPubMedGoogle Scholar
  • 35 Cotner T, Williams JM, Cristenson L, Shapiro HM, Strom TB, Strominger J. Simultaneous flow cytometric analysis of human T-cell activation antigen expression and DNA content. J Exp Med 1983; 157: 461-472
    CrossrefPubMedGoogle Scholar
  • 36 Nouri-Aria KT, Magrin S, Alexander GJM, Anderson MG, Williams R, Eddleston ALWF. Abnormal T-cell activation in chronic hepatitis B viral infection: a consequence of monocyte dysfunction?. Immunology 1988; 64: 733-738
    PubMedGoogle Scholar
  • 37 Robbins PA, Maino VC, Warner NL, Brodsky FM. Activated T cells and monocytes have characteristic patterns of class II antigen expression. J Immunol 1988; 141: 1281-1287
    PubMedGoogle Scholar
  • 38 Schramm W, Roggendorf M, Rommel F, Kammerer R, Pohlmann H, Rashofer R, Gurtler L, Deinhardt F. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut 1989; 59: 390-392
    CrossrefPubMedGoogle Scholar
  • 39 Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of haemophilia patients. Blood 1990; 76: 254-256
    PubMedGoogle Scholar
  • 40 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-1863
    PubMedGoogle Scholar
  • 41 Roosendaal FR, Varekamp I, Smit C, Bröcker-Vriends AHJT, Dijck Hv, Van den Broucke JP, Hermans J, Suurmeijer TPBM, Briët E. Mortality and causes of death in Dutch haemophiliacs 1973-86. Br J Haematol 1989; 71: 71-76
    CrossrefPubMedGoogle Scholar
  • 42 Hay C. Purity aspects of ultra-pure concentrates: is pure better?. R Soc Med Serv, Round Table Ser 1991; 25: 69-77
    PubMedGoogle Scholar